Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

schering health care ltd - norgestrel - oral tablet - 75microgram

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

schering health care ltd - not applicable

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

schering health care ltd - hydroxyprogesterone caproate - solution for injection - 250mg/1ml

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

schering health care ltd - levonorgestrel; ethinylestradiol - oral tablet - 250microgram ; 50microgram

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

schering health care ltd - alemtuzumab - solution for infusion - 10mg/1ml

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

schering health care ltd - palmitic acid; galactose - powder and solvent for suspension for injection - 2.5mg ; 2.49gram

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

schering health care ltd - palmitic acid; galactose - powder and solvent for suspension for injection - 4mg ; 3.99gram

Izrael - angličtina - Ministry of Health

merck sharp & dohme israel ltd - ribavirin - capsules - ribavirin 200 mg - ribavirin - ribavirin - tritherapy:rebetol in combination with boceprevir and peginterferon alfa-2b is indicated for the treatment of chronic hepatitis c (chc) genotype1 infection in adults patients (18 years of age and older) with compensated liver disease who are previously untreated or who have failed previous therapy.bitherapy:rebetol is indicated for the treatment of chronic hepatitis c virus infection in adults and must only be used as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b .rebetol monotherapy must not be used. there is no safety or efficacy information on the use of rebetol with other forms of interferon (i.e., not alfa-2b).previously untreated (naïve) patientsadult patients (18 years of age or older): rebetol is indicated for:• tritherapy- in combination with peginterferon alfa-2b and boceprevir for the treatment of adult patients with chronic hepatitis c genotype1 infection with compensated liver disease.• bitherapy- in combination with interferon alfa-2b or peginterferon alfa-2b, fo

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - losartan potassium - film-coated tablet - 50 milligram(s) - losartan

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - losartan potassium - film-coated tablet - 100 milligram(s) - losartan